VetaMeg

Manufacturer
Aspen Veterinary Resources | Bimeda Inc. | Bimeda-MTC
Effective date
2024-03-13
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
10
Source
full-release
Hydrated at
2026-06-01 02:42:54

Label at a glance#

ProductVetaMeg
Active ingredientFLUNIXIN MEGLUMINE
Label structure4 sections

Storage and handling

Store at 20°C - 25°C (68°F - 77°F); excursions permitted between 15°C - 30°C (between 59°F - 86°F) See product information sheet for additional information. Approved by FDA under ANADA # 200-581

Label contents#

Full prescribing information#

WARNINGS AND PRECAUTIONS SECTION

VetaMeg® Equine Paste
(flunixin meglumine paste)

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Each 30-g syringe of VetaMeg Equine Paste contains flunixin meglumine equivalent to 1500 mg flunixin.

INDICATIONS: VetaMeg Equine Paste is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.

ACTIVITY: Flunixin meglumine is a potent, nonnarcotic, nonsteroidal analgesic agent with anti-inflammatory and antipyretic activity, It is significantly more potent than pentazocine, meperidine, and codeine as an analgesic in the rat yeast paw test. Oral studies in the horse show onset of flunixin activity occurs withing 2 hours of administration. Peak response occurs between 12 and 16 hours and duration of activity is 24-36 hours.

CONTRAINDICATIONS: There are no known contraindications to this drug when used as directed.

WARNING: Do not use in horses intended for human consumption.

PRECAUTIONS: The effect of flunixin meglumine on pregnancy has not been determined. Studies to date show there is no detrimental effect on stallion spermatogenesis with or following the recommended dose of flunixin meglumine.

SIDE EFFECTS: During field studies with flunixin meglumine, no significant side effects were reported.

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Aspen Veterinary Resources at info@aspenveterinaryresources.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

DOSAGE & ADMINISTRATION SECTION

DOSAGE AND ADMINISTRATION: The recommended dose of flunixin meglumine is 0.5 mg per lb of body weight once daily. The VetaMeg Equine Paste syringe, calibrated in twelve 250-lb weight increments, delivers 125 mg of flunixin for each 250 lbs (see dosage table). One syringe will treat a 1000-lb horse once daily for 3 days, or three 1000-lb horses one time.

DOSAGE TABLE

 Syringe Mark* Horse Weight (lbs) VetaMeg™ Equine Paste Delevered (g)mg Flunixin Delivered 
 0 --- --- ---
 250 250 2.5 125
 500 500 5.0 250
 750 750 7.5 375
 1000 1000 10.0 500

* Use dial edge nearest syringe barrel to mark dose.

The paste is orally administered by inserting the nozzle of the syringe through the interdental space, and depositing the required amount of paste on the back of the tongue by depressing the plunger.

Treatment may be given initially by intravenous or intramuscular injection of VetaMeg Injectable Solution, followed by VetaMeg Equine Paste on Days 2 to 5. Flunixin meglumine treatment should not exceed 5 consecutive days.

TOXICITY: No toxic effects were observed in rats given oral flunixin meglumine 2 mg/kg per day for 42 days. Higher doses produced ulceration of the gastrointestinal tract. The emetic dose in dogs is between 150 and 250 mg/kg. Flunixin was well tolerated in monkeys dosed daily with 4 mg/kg for 56 days. No adverse effects occurred in horses dosed orally with 1.0 or 1.5 mg/lb for 5 consecutive days.

STORAGE AND HANDLING SECTION

Store at 20°C - 25°C (68°F - 77°F); excursions permitted between 15°C - 30°C (between 59°F - 86°F)

See product information sheet for additional information.

Approved by FDA under ANADA # 200-581

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

image descriptionimage description

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1603396flunixin 1500 MG Oral Paste [Vetameg]SBD10
1603384flunixin 1500 MG Oral PasteSCD10
1603396Vetameg 1500 MG Oral PasteSY10

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
46066-503-01VetaMeg30 g in 1 SYRINGEPASTE3010

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
46066-503VETAMEG (FLUNIXIN MEGLUMINE) PASTE [ASPEN VETERINARY RESOURCES]101 package rows20240315_375a929b-276e-472c-a0b0-35b0e656363d.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
FLUNIXIN MEGLUMINEACTIVE INGREDIENT8Y3JK0JW3U3
FLUNIXINACTIVE MOIETY356IB1O4003

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
46066-50346066-503-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 1 matching rows.

Name, UNII, Kind table
NameUNIIKind
FLUNIXIN MEGLUMINE8Y3JK0JW3UACTIB

Source Document#

Source XML

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.